ENLV

Enlivex Therapeutics Ltd.

Investor Moves

NameValueActionChangePriceCurrent Price
Jim SimonsRenaissance Technologies
$119k128.2k shares
TrimQ1 2026
$101k
$0.9301
$0.7644
Ken GriffinCitadel Advisors
$48k52.1k shares
AddQ1 2026
$5.6k
$0.9301
$0.7644
Jim SimonsRenaissance Technologies
$221k313.6k shares
ExitQ4 2025
$164k
$0.7032
$0.7644
Ken GriffinCitadel Advisors
$43k60.9k shares
ExitQ4 2025
$72k
$0.7032
$0.7644
Jim SimonsRenaissance Technologies
$221k313.6k shares
AddQ4 2025
$57k
$0.7032
$0.7644
Ken GriffinCitadel Advisors
$43k60.9k shares
TrimQ4 2025
$29k
$0.7032
$0.7644

News

globenewswire.comEnlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritisglobenewswire.comJun 15globenewswire.comENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026globenewswire.comJun 2globenewswire.comAllocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026globenewswire.comJun 1globenewswire.comEnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Boardglobenewswire.comMay 28globenewswire.comEnlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidityglobenewswire.comMay 27